HORSHAM, Pa., Nov. 12, 2015 (GLOBE NEWSWIRE) -- MELA Sciences, Inc. (NASDAQ:MELA), a medical technology company dedicated to developing and commercializing innovative products for the treatment and diagnosis of serious dermatological disorders, today reported financial results for the third quarter ended September 30, 2015.
Third Quarter and Recent Corporate Highlights
- Third quarter revenue for the acquired businesses was $8.2 million in line with expectations.
- The installed base of XTRAC systems in the U.S. expanded to 698 systems, up from 590 at the end of the third quarter 2014, as reported to us by PhotoMedex.
- Achieved positive non-GAAP adjusted income in first full quarter of combined operations. See Non-GAAP Measures below.
- Integration of the acquired businesses into MELA is essentially complete.
MELA Sciences acquired the XTRAC and VTRAC business from PhotoMedex, Inc. on June 22, 2015. Therefore, operating results for the three and nine months ended September 30, 2015 include activity from the XTRAC and VTRAC businesses from July 1, 2015 through September 30, 2015 for the three-month period and from June 23, 2015 through September 30, 2015 for the nine-month period. As a result of purchase accounting rules, the operating results of the XTRAC and VTRAC businesses for the three and nine months ended September 30, 2014 are not included in consolidated statements of operations for the periods ended September 30, 2014.
Commenting on the third quarter, Michael R. Stewart, President and CEO stated: "The XTRAC recurring revenue in the third quarter continued to show positive growth of over 5%. The installed base of placed lasers in the United States also increased by 5% to nearly 700 lasers. The average annualized revenue per system now exceeds $42,000. All of these results met our expectations and demonstrate the integration of the XTRAC business into MELA has successfully occurred."
Continuing, Stewart added: "The transforming of MELA is well underway. In addition to the integration activities that have been accomplished thus far, we are now reviewing new branding initiatives that we expect to implement before the end of 2015 that we believe will better reflect the new company and the market that we serve."
Reported Financial Results
Revenues for the third quarter of 2015 were $8.3 million compared with revenues for the third quarter of 2014 of $0.2 million, which did not include revenues from the XTRAC and VTRAC businesses.
Net loss for the third quarter of 2015 was $12.2 million or ($1.29) per share, which included a non-cash deemed dividend of $3.0 million, other expense of $1.3 million for the change in fair value of warrant liability, $5.6 million in interest expense and $1.7 million in depreciation and amortization expenses. This compares with a net loss for the third quarter of 2014 of $2.3 million or ($0.44) per share, which included other income of $2.1 million for the change in fair value of warrant liability, $0.5 million in interest expense and $0.5 million in depreciation and amortization expenses.
Revenues for the nine months of 2015 were $9.0 million compared with revenues for the nine months of 2014 of $0.5 million, which did not include revenues from the XTRAC and VTRAC businesses.
Net loss for the nine months of 2015 was $27.3 million or ($3.42) per share, which included a non-cash deemed dividend of $3.0 million, other expense of $0.7 million for the change in fair value of warrant liability, $4.8 million in inventory obsolescence charges; $8.7 million in interest expense; $0.5 million in acquisition costs and $2.3 million in depreciation and amortization expenses. This compares with net loss for the nine months of 2014 of $9.6 million or ($1.89) per share, which included other income of $7.2 million for the change in fair value of warrant liability, $3.4 million in registration rights liquidated damages, $0.5 million in interest expense and $1.4 million in depreciation and amortization expenses.
As of September 30, 2015 the company had cash, cash equivalents and short-term investments of $3.3 million including $0.1 million of restricted cash, compared with $11.4 million of unrestricted cash as of December 31, 2014.
Non-GAAP Measures
To supplement the Company's consolidated financial statements, prepared in accordance with GAAP, the Company provides certain non-GAAP measures of financial performance. These non-GAAP measures include non-GAAP adjusted income.
The Company's reference to these non-GAAP measures should be considered in addition to results prepared under current accounting standards, but are not a substitute for, nor superior to, GAAP results. These non-GAAP measures are provided to enhance investors' overall understanding of our current financial performance and to provide further information for comparative purposes.
Specifically, the Company believes the non-GAAP measures provide useful information to both management and investors by isolating certain expenses, gains and losses that may not be indicative of the Company's core operating results and business outlook. In addition, the Company believes non-GAAP measures enhance the comparability of results against prior periods. Reconciliation to the most directly comparable GAAP measure of all non-GAAP measures included in this press release is as follows:
| (Unaudited) | ||||
| Three Months Ended | Nine Months Ended | |||
| September 30, | September 30, | |||
| (in thousands) | 2015 | 2014 | 2015 | 2014 |
| Net loss income as reported | ($9,234) | ($2,288) | ($24,354) | ($9,641) |
| Adjustments: | ||||
| Depreciation and amortization expense | 1,710 | 489 | 2,348 | 1,371 |
| Interest expense, net | 506 | 104 | 794 | 105 |
| Non-cash interest expense | 5,071 | 423 | 7,944 | 423 |
| EBITDA | (1,947) | (1,272) | (13,268) | (7,742) |
| Stock-based compensation expense | 1,007 | 115 | 1,483 | 447 |
| Acquisition costs | -- | -- | 456 | -- |
| Change in fair value of warrants | 1,329 | (2,108) | 679 | (7,151) |
| Registration rights liquidated charges | -- | -- | -- | 3,420 |
| Impairment of property and equipment | -- | -- | 920 | -- |
| Inventory obsolescence charges | -- | -- | 4,818 | -- |
| Non-GAAP adjusted income ( loss ) | $389 | ($3,265) | ($4,912) | ($11,026) |
MELA previously announced the scheduling of a conference call with investors to review the results of the Third quarter. The following is the pertinent information for accessing that call.
| Conference Call Detail: | ||
| Date: | Thursday, November 12 | |
| Time: | 4:30 pm Eastern Time | |
| Toll Free: | 888-430-8691 | |
| International: | 719-325-2376 | |
| Passcode: | 714691 | |
| Webcast: | www.melasciences.com | |
| Replays, available through November 26, 2015 | ||
| Toll Free: | 877-870-5176 | |
| International: | 858-384-5517 | |
| Replay PIN: | 714691 | |
About MELA Sciences, Inc. (www.melasciences.com)
MELA Sciences is a medical technology company focused on the dermatology market. Its products include the XTRAC® laser and VTRAC® excimer lamp systems utilized in the treatment of psoriasis, vitiligo and various other skin conditions, and the MelaFind® system used to assist in the identification and management of melanoma skin cancer.
Safe Harbor
This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company's plans, objectives, expectations and intentions and may contain words such as "will," "may," "seeks," and "expects," that suggest future events or trends. These statements, including the Company's ability to generate the anticipated revenue stream from the acquired business, the Company's ability to generate sufficient cash flow to fund the Company's ongoing operations beginning in 2015 or at any time in the future, including support for the MelaFind system through the reimbursement process and the Company's ability to integrate and transition the acquired business effectively and build a leading franchise in medical dermatology, are based on the Company's current expectations and are inherently subject to significant uncertainties and changes in circumstances. Actual results may differ materially from the Company's expectations due to financial, economic, business, competitive, market, regulatory and political factors or conditions affecting the Company and the medical device industry in general, as well as more specific risks and uncertainties set forth in the Company's SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all of these forward-looking statements may prove to be incorrect or unreliable. The Company assumes no duty to update its forward-looking statements and urges investors to carefully review its SEC disclosures available at www.sec.gov and www.melasciences.com.
| MELA SCIENCES, INC. AND SUBSIDIARY | ||
| CONDENSED CONSOLIDATED BALANCE SHEETS | ||
| (In thousands) | ||
| September 30, 2015 | December 31, 2014 | |
| ASSETS | (unaudited) | |
| Current assets: | ||
| Cash and cash equivalents | $3,169 | $11,434 |
| Restricted cash | 100 | -- |
| Accounts receivable, net | 4,182 | 220 |
| Inventories, net | 3,915 | 5,275 |
| Other current assets | 596 | 274 |
| Property and equipment, net | 14,461 | 1,961 |
| Goodwill and other intangible assets | 24,608 | 37 |
| Other non-current assets, net | 1,123 | 869 |
| Total assets | $52,154 | $20,070 |
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||
| Current liabilities: | ||
| Senior Note payable and other notes payable | $8,887 | $ -- |
| Accounts payable and accrued current liabilities | 6,113 | 2,144 |
| Current portion of deferred revenues | 267 | 43 |
| Senior secured convertible debentures, net | 11,373 | 5,001 |
| Warrant liability | 9,535 | 499 |
| Other long-term liabilities | 103 | 107 |
| Stockholders' equity | 15,876 | 12,276 |
| Total liabilities and stockholders' equity | $52,154 | $20,070 |
| MELA SCIENCES, INC. AND SUBSIDIARY | ||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||
| (In thousands, except share and per share amounts) | ||||
| (unaudited) | ||||
|
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||
| 2015 | 2014 | 2015 | 2014 | |
| Revenues | $8,323 | $218 | $9,015 | $541 |
| Cost of revenues | 3,042 | 1,560 | 10,226 | 3,755 |
| Gross profit (loss) | 5,281 | (1,342) | (1,211) | (3,214) |
| Operating expenses: | ||||
| Engineering and product development | 471 | 345 | 946 | 1,423 |
| Selling and marketing | 4,001 | 429 | 5,984 | 2,366 |
| General and administrative | 3,132 | 1,885 | 6,819 | 5,988 |
| 7,604 | 2,659 | 13,749 | 9,777 | |
| Operating loss before other income (expense), net | (2,323) | (4,001) | (14,960) | (12,991) |
| Other income (expense), net: | ||||
| Interest expense, net | (5,577) | (527) | (8,738) | (528) |
| Change in fair value of warrant liability | (1,329) | 2,108 | (679) | 7,151 |
| Registrations rights liquidated damages | -- | -- | -- | (3,420) |
| Gain on sale of assets | -- | 11 | -- | 16 |
| Other (expense) income, net | (5) | 121 | 23 | 131 |
| (6,911) | 1,713 | (9,394) | 3,350 | |
| Net loss | (9,234) | (2,288) | (24,354) | (9,641) |
| Deemed dividend related to warrant modification | (2,962) | -- | (2,962) | -- |
| Net loss attributable to common stockholders | ($12,196) | ($2,288) | ($27,316) | ($9,641) |
| Basic and diluted net loss per share | ($1.29) | ($0.44) | ($3.42) | ($1.89) |
| Shares used in computing basic and diluted net loss per share | 9,442,022 | 5,216,290 | 7,994,012 | 5,108,418 |
| MELA SCIENCES, INC. AND SUBSIDIARY | ||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||
| (In thousands, unaudited) | ||
| For the Nine Months Ended September 30, | ||
| 2015 | 2014 | |
| Cash Flows From Operating Activities: | ||
| Net loss | ($24,354) | ($9,641) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 2,347 | 1,371 |
| Stock-based compensation | 1,483 | 447 |
| Impairment of long-lived assets | 920 | -- |
| Inventory write-offs | 4,818 | 1,076 |
| Amortization of debt discount | 7,571 | 385 |
| Amortization of deferred financing costs | 373 | 38 |
| Change in fair value of warrant liability | 679 | (7,151) |
| Other | 20 | 1 |
| Changes in operating assets and liabilities: | ||
| Current assets | (1,016) | (966) |
| Current liabilities | 114 | (212) |
| Net cash used in operating activities | (7,045) | (14,668) |
| Cash Flows From Investing Activities: | ||
| Lasers placed-in-service, net | (1,066) | -- |
| Acquisition costs, net of cash received | (42,500) | -- |
| Other | (17) | 17 |
| Net cash (used in) provided by investing activities | (43,583) | 17 |
| Cash Flows From Financing Activities: | ||
| Proceeds from convertible debentures | 32,500 | 15,000 |
| Proceeds from senior notes | 10,000 | -- |
| Proceeds from credit facilities | -- | 11,452 |
| Other financing activities | (154) | (1,123) |
| Net cash provided by financing activities | 42,346 | 25,335 |
| Effect of exchange rate changes on cash | 17 | -- |
| Net (decrease)/increase in cash and cash equivalents | (8,265) | 10,684 |
| Cash and cash equivalents, beginning of period | 11,434 | 3,783 |
| Cash and cash equivalents, end of period | $3,169 | $14,467 |
| Supplemental information: | ||
| Cash paid for interest | $402 | $ -- |
| Supplemental information of non-cash investing and financing activities | ||
| Conversion of senior secured convertible debentures into common stock | $4,593 | $ -- |
| Establishment of a warrant liability with a deemed dividend | $2,962 | $ -- |
| Exchange of series A convertible preferred stock for series B convertible preferred stock | $ -- | $12,300 |
| Recognition of debt discount and beneficial conversion feature on long-term debt | $27,300 | $10,353 |
| Reclassification of property and equipment to inventory, net | $107 | $ -- |
| Reclassification of warrant liability (from) to stockholders' equity | ($5,399) | $ -- |